Literature DB >> 21994452

Identification and characterization of an immunogenic hybrid epitope formed by both HIV gp120 and human CD4 proteins.

George K Lewis1, Timothy R Fouts, Sani Ibrahim, Brian M Taylor, Rachita Salkar, Yongjun Guan, Roberta Kamin-Lewis, James E Robinson, Anthony L Devico.   

Abstract

Certain antibodies from HIV-infected humans bind conserved transition state (CD4 induced [CD4i]) domains on the HIV envelope glycoprotein, gp120, and demonstrate extreme dependence on the formation of a gp120-human CD4 receptor complex. The epitopes recognized by these antibodies remain undefined although recent crystallographic studies of the anti-CD4i monoclonal antibody (MAb) 21c suggest that contacts with CD4 as well as gp120 might occur. Here, we explore the possibility of hybrid epitopes that demand the collaboration of both gp120 and CD4 residues to enable antibody reactivity. Analyses with a panel of human anti-CD4i MAbs and gp120-CD4 antigens with specific mutations in predicted binding domains revealed one putative hybrid epitope, defined by the human anti-CD4i MAb 19e. In virological and immunological tests, MAb 19e did not bind native or constrained gp120 except in the presence of CD4. This contrasted with other anti-CD4i MAbs, including MAb 21c, which bound unliganded, full-length gp120 held in a constrained conformation. Conversely, MAb 19e exhibited no specific reactivity with free human CD4. Computational modeling of MAb 19e interactions with gp120-CD4 complexes suggested a distinct binding profile involving antibody heavy chain interactions with CD4 and light chain interactions with gp120. In accordance, targeted mutations in CD4 based on this model specifically reduced MAb 19e interactions with stable gp120-CD4 complexes that retained reactivity with other anti-CD4i MAbs. These data represent a rare instance of an antibody response that is specific to a pathogen-host cell protein interaction and underscore the diversity of immunogenic CD4i epitope structures that exist during natural infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21994452      PMCID: PMC3233132          DOI: 10.1128/JVI.05072-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Structure of a V3-containing HIV-1 gp120 core.

Authors:  Chih-chin Huang; Min Tang; Mei-Yun Zhang; Shahzad Majeed; Elizabeth Montabana; Robyn L Stanfield; Dimiter S Dimitrov; Bette Korber; Joseph Sodroski; Ian A Wilson; Richard Wyatt; Peter D Kwong
Journal:  Science       Date:  2005-11-11       Impact factor: 47.728

2.  Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Authors:  Emma T Crooks; Penny L Moore; Douglas Richman; James Robinson; Jeffrey A Crooks; Michael Franti; Norbert Schülke; James M Binley
Journal:  Hum Antibodies       Date:  2005

Review 3.  Antibody vs. HIV in a clash of evolutionary titans.

Authors:  Dennis R Burton; Robyn L Stanfield; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-11       Impact factor: 11.205

4.  Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.

Authors:  E S Gray; P L Moore; I A Choge; J M Decker; F Bibollet-Ruche; H Li; N Leseka; F Treurnicht; K Mlisana; G M Shaw; S S Abdool Karim; C Williamson; L Morris
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Kinetic rates of antibody binding correlate with neutralization sensitivity of variant simian immunodeficiency virus strains.

Authors:  Jonathan D Steckbeck; Irina Orlov; Andrew Chow; Heather Grieser; Kenneth Miller; JoAnne Bruno; James E Robinson; Ronald C Montelaro; Kelly Stefano Cole
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

7.  Human CD4 binds immunoglobulins.

Authors:  P Lenert; D Kroon; H Spiegelberg; E S Golub; M Zanetti
Journal:  Science       Date:  1990-06-29       Impact factor: 47.728

8.  Structure of an unliganded simian immunodeficiency virus gp120 core.

Authors:  Bing Chen; Erik M Vogan; Haiyun Gong; John J Skehel; Don C Wiley; Stephen C Harrison
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

9.  Antigenic conservation and immunogenicity of the HIV coreceptor binding site.

Authors:  Julie M Decker; Frederic Bibollet-Ruche; Xiping Wei; Shuyi Wang; David N Levy; Wenquan Wang; Eric Delaporte; Martine Peeters; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Michael S Saag; James A Hoxie; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

10.  PatchDock and SymmDock: servers for rigid and symmetric docking.

Authors:  Dina Schneidman-Duhovny; Yuval Inbar; Ruth Nussinov; Haim J Wolfson
Journal:  Nucleic Acids Res       Date:  2005-07-01       Impact factor: 16.971

View more
  12 in total

1.  Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma.

Authors:  Mohammad M Sajadi; George K Lewis; Michael S Seaman; Yongjun Guan; Robert R Redfield; Anthony L DeVico
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

2.  Range of CD4-Bound Conformations of HIV-1 gp120, as Defined Using Conditional CD4-Induced Antibodies.

Authors:  Gilad Kaplan; Anna Roitburd-Berman; George K Lewis; Jonathan M Gershoni
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

Review 3.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

4.  Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.

Authors:  Daniel P Leaman; Jeong Hyun Lee; Andrew B Ward; Michael B Zwick
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.

Authors:  Yuxing Li; Sijy O'Dell; Richard Wilson; Xueling Wu; Stephen D Schmidt; Carl-Magnus Hogerkorp; Mark K Louder; Nancy S Longo; Christian Poulsen; Javier Guenaga; Bimal K Chakrabarti; Nicole Doria-Rose; Mario Roederer; Mark Connors; John R Mascola; Richard T Wyatt
Journal:  J Virol       Date:  2012-08-08       Impact factor: 5.103

6.  Full Length Single Chain Fc Protein (FLSC IgG1) as a Potent Antiviral Therapy Candidate: Implications for In Vivo Studies.

Authors:  Olga S Latinovic; Sandra Medina-Moreno; Kate Schneider; Neelakshi Gohain; Juan Zapata; Marzena Pazgier; Marvin Reitz; Joseph Bryant; Robert R Redfield
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-22       Impact factor: 2.205

7.  Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding.

Authors:  Yongjun Guan; Marzena Pazgier; Mohammad M Sajadi; Roberta Kamin-Lewis; Salma Al-Darmarki; Robin Flinko; Elena Lovo; Xueji Wu; James E Robinson; Michael S Seaman; Timothy R Fouts; Robert C Gallo; Anthony L DeVico; George K Lewis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-13       Impact factor: 11.205

8.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

9.  Probing the Structure of the HIV-1 Envelope Trimer Using Aspartate Scanning Mutagenesis.

Authors:  Raksha Das; Rohini Datta; Raghavan Varadarajan
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

10.  Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Klara Sirokman; Avishek Nandi; Karin Hartog; Ying Lian; Anthony R Geonnotti; David Montefiori; Michael Franti; Grégoire Martin; Andrea Carfi; Pascal Kessler; Loïc Martin; Indresh K Srivastava; Susan W Barnett
Journal:  PLoS One       Date:  2012-01-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.